Based on Kaiser formulary bulletins and member-reported experiences, most regions require the following before approving Wegovy: Clinical eligibility: BMI of 30 kg/m or greater, or BMI of 27 kg/m or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea) Documentation that the member has participated in a Kaiser-affiliated lifestyle or behavioral weight-management program for a minimum of 3 to 6 months Lab work within the past 6 months including fasting glucose, HbA1c, lipid panel, and thyroid function Prescriber requirements: The prescribing physician must be a Kaiser-employed or contracted provider A referral to Kaiser's obesity-medicine or endocrinology department is typically required before the PA can be submitted The obesity-medicine specialist's notes must confirm medical necessity The clinical rationale for these layers traces back to the STEP-1 trial (N=1,961), which demonstrated 14.9% mean body-weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo
Endocrine, 60 (3), 423434
It's composed of three amino acids: glutamine, glycine, and cysteine, which are found in various foods and can be synthesized by the body
Even a single overnight temperature excursion above 8C compromises the 28-day beyond-use date
Understanding Your Fasting Glucose Levels Fasting glucose levels indicate how well your body is managing blood sugar
This broad availability is particularly important for managing widespread health issues like obesity and diabetes, which affect millions of people
